CLICK HERE TO REGISTER
Adverse Drug Reactions (ADRs) to medications account for 6.5% of UK hospital admissions, admissions related to ADRs cost the NHS an estimated £530m annually. Genetic variants in an individual can be tested to predict the likelihood of a particular drug being therapeutic, genetic variants can also predict the likelihood of treatment causing unintended harm through a ADR. The study of how genes affect a person’s response to drugs is known as Pharmacogenomics.
Increasingly, genomic testing is becoming embedded in the NHS and informing care & treatment decisions. As the largest prescriber of medicines in the NHS and the overseer of many Long Term Conditions, primary care will, in time, benefit from pharmacogenomic testing to help aid & inform clinical prescribing decisions.
Join this educational webinar to find out more about pharmacogenomics with a primary care lens.
Speaker:
-
Dharmisha ChauhanLead PharmacistNHS North Thames Genomic Medicines Service AllianceDharmisha Chauhan is the Lead Pharmacist for the North Thames Genomic Medicines Service Alliance which is hosted by Great Ormond Street Hospital. She has a specialist interest in precision medicine and the role of pharmacogenetics to improve patient outcomes and safety. Dharmisha also has 12 years of oncology experience with expertise in lung, sarcoma, skin and melanoma cancers and works clinically at the Royal Marsden NHS Foundation Trust. Her interests include the role of genomics and immunotherapy biomarkers within clinical pharmacy practice, especially in rare cancers. Dharmisha has collaborated on a range local and national pharmacogenetics and cancer projects, the most recent focusing on the role of pharmacogenetics within mental health care clinical pathways.
